European Parliament
2014-2019

Plenary sitting

B8-1407/2016

21.12.2016

MOTION FOR A RESOLUTION

pursuant to Rule 133 of the Rules of Procedure

on the risks associated with the use of Essure sterilisation implants

Mireille D'Ornano

B8-1407/2016

Motion for a European Parliament resolution on the risks associated with the use of Essure sterilisation implants

The European Parliament,

– having regard to Articles 4, 6 and 9 of the Treaty on the Functioning of the European Union,

– having regard to Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency,

– having regard to Rule 133 of its Rules of Procedure,

A. whereas the European Medicines Agency (EMA) has a remit to protect public health by evaluating medicines, particularly when undesirable effects are reported;

B. whereas Essure sterilisation implants, manufactured by Bayer, are currently suspected of causing haemorrhagic, neurological and muscular disorders, suspicions that are sufficiently strong for a thousand women already to have brought legal proceedings against the manufacturer in the United States;

C. whereas, according to the manufacturer, since 2001 around one million units of this medical device have been sold worldwide, including 240 000 in France;

1. Calls on the Commission:

   – to ask the EMA to conduct an investigation with the aim of rapidly securing an assurance that these devices are harmless;

   – to take appropriate measures if the devices present any more than a negligible risk to the health of women using them.